23155-120 : Acetazolamide 500 mg 12 Hr Extended Release Capsule


NDC: 23155-120
Labeler: Heritage Pharmaceuticals Inc.
Product Type: Human Prescription Drug
Drug Name:  Acetazolamide
Dosage Form: Oral Capsule, Extended Release
Application #: ANDA090779
Rev. Date: 


Appearance:


Markings: HP120
Shapes:  Capsule
Colors:  Green
Size (mm): 23
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

HP120: (23155-120) Acetazolamide 500 mg 12 Hr Extended Release Capsule by Heritage Pharmaceuticals Inc.
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.

NDC Package Codes:

  • 23155-120-01: 100 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (23155‑120‑01)
  • 23155-120-05: 500 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (23155‑120‑05)

Active Ingredients:

  • Acetazolamide

Dosage Strength:

  • 500 mg

Inactive Ingredients:

  • Cellulose, Microcrystalline
  • Sodium Lauryl Sulfate
  • Hydroxypropyl Cellulose
  • Talc
  • Fd&c Green No. 3
  • Ferrosoferric Oxide
  • Ferric Oxide Yellow
  • Titanium Dioxide
  • Gelatin
  • Shellac
  • Propylene Glycol
  • Potassium Hydroxide

Pharmaceutical Classes:

  • Carbonic Anhydrase Inhibitor [EPC]
  • Carbonic Anhydrase Inhibitors [MoA]
  • Sulfonamides [CS]

Related Products:

Based on records with the same trade name.
  • 23155-287 Acetazolamide 125 mg Oral Tablet by Heritage Pharmaceuticals Inc.
  • 23155-288 Acetazolamide 250 mg Oral Tablet by Heritage Pharmaceuticals Inc.
  • 23155-313 Acetazolamide 500 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Heritage Pharmaceuticals Inc.
  • 23155-787 Acetazolamide 500 mg Oral Capsule, Extended Release by Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc.
  • 23155-831 Acetazolamide 500 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc.
  • 0143-9006 Acetazolamide 500 mg Intravenous Injection, Powder, Lyophilized, for Solution by Hikma Pharmaceuticals USA Inc.
  • 0143-9503 Acetazolamide 500 mg Intravenous Injection, Powder, Lyophilized, for Solution by West-ward Pharmaceuticals Corp
  • 0179-0050 Acetazolamide 500 mg 12 Hr Extended Release Capsule by Kaiser Foundation Hospitals
  • 0527-1050 Acetazolamide 250 mg Oral Tablet by Lannett Company, Inc.
  • 0555-0513 Acetazolamide 500 mg 12 Hr Extended Release Capsule by Barr Laboratories Inc..
  • 0615-1511 Acetazolamide 250 mg Oral Tablet by Ncs Healthcare of Ky, Inc Dba Vangard Labs
  • 0904-6663 Acetazolamide 250 mg Oral Tablet by Major Pharmaceuticals
  • 10135-567 Acetazolamide 250 mg Oral Tablet by Marlex Pharmaceuticals Inc
  • 10135-772 Acetazolamide 125 mg Oral Tablet by Marlex Pharmaceuticals, Inc.
  • 10135-773 Acetazolamide 250 mg Oral Tablet by Marlex Pharmaceuticals, Inc.
  • 16729-331 Acetazolamide 500 mg Oral Capsule, Extended Release by Accord Healthcare Inc.
  • 25021-817 Acetazolamide 500 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Sagent Pharmaceuticals
  • 27241-132 Acetazolamide 125 mg Oral Tablet by Ajanta Pharma USA Inc.
  • 27241-133 Acetazolamide 250 mg Oral Tablet by Ajanta Pharma USA Inc.
  • 29033-030 Acetazolamide 500 mg Oral Capsule, Extended Release by Nostrum Laboratories, Inc.
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 23155-120 QR Code

< Prev: 23155-119Next: 23155-121 >

Related Discussions:

Acetazolamide (Diamox)
What are the main side effects of Diamox (Acetazolamide) Slow Release Tablets? ## Hello, D. Thomas! How are you? And at ... 1 reply




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.